WO2010151080A2 - 카르복시로자탄을 함유하는 약학 조성물 및 이의 제조방법 - Google Patents
카르복시로자탄을 함유하는 약학 조성물 및 이의 제조방법 Download PDFInfo
- Publication number
- WO2010151080A2 WO2010151080A2 PCT/KR2010/004152 KR2010004152W WO2010151080A2 WO 2010151080 A2 WO2010151080 A2 WO 2010151080A2 KR 2010004152 W KR2010004152 W KR 2010004152W WO 2010151080 A2 WO2010151080 A2 WO 2010151080A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- polyethylene glycol
- water
- soluble polymer
- copolymer
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
- 238000004519 manufacturing process Methods 0.000 title abstract description 5
- ZEUXAIYYDDCIRX-UHFFFAOYSA-N losartan carboxylic acid Chemical compound CCCCC1=NC(Cl)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C2=NNN=N2)C=C1 ZEUXAIYYDDCIRX-UHFFFAOYSA-N 0.000 title abstract description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 25
- 239000002202 Polyethylene glycol Substances 0.000 claims description 23
- 229920003169 water-soluble polymer Polymers 0.000 claims description 23
- 239000007962 solid dispersion Substances 0.000 claims description 18
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 8
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 229960000913 crospovidone Drugs 0.000 claims description 6
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 6
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 6
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 6
- 229920002554 vinyl polymer Polymers 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- CRVGKGJPQYZRPT-UHFFFAOYSA-N diethylamino acetate Chemical compound CCN(CC)OC(C)=O CRVGKGJPQYZRPT-UHFFFAOYSA-N 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims description 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 2
- 239000011118 polyvinyl acetate Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 1
- 235000010413 sodium alginate Nutrition 0.000 claims 1
- 239000000661 sodium alginate Substances 0.000 claims 1
- 229940005550 sodium alginate Drugs 0.000 claims 1
- 238000010828 elution Methods 0.000 abstract description 16
- 238000004090 dissolution Methods 0.000 description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 239000012738 dissolution medium Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229910002012 Aerosil® Inorganic materials 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 5
- 229940069328 povidone Drugs 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- -1 2 '-(1H-tetrazol-5-yl) [1,1'-biphenyl] -4-yl Chemical group 0.000 description 3
- 102000008873 Angiotensin II receptor Human genes 0.000 description 3
- 108050000824 Angiotensin II receptor Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229940079832 sodium starch glycolate Drugs 0.000 description 3
- 229920003109 sodium starch glycolate Polymers 0.000 description 3
- 239000008109 sodium starch glycolate Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229910021485 fumed silica Inorganic materials 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000010309 melting process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the dissolution rate and dissolution deviation are improved carboxylojatan (losartan carboxylic acid, 2-butyl-4-chloro-1-[(2 '-(1H-tetrazol-5-yl) [1,1'-biphenyl) ] -4-yl) methyl] -1H-imidazole-5-carboxylic acid ⁇ and pharmaceutical preparation method thereof.
- Carboxylozatan (2-butyl-4-chloro-1-[(2 '-(1H-tetrazol-5-yl) [1,1'-biphenyl] -4-yl) methyl] methyl]- 1H-imidazole-5-carboxylic acid ⁇ has an angiotensin II receptor antagonistic effect and can be used for the treatment of hypertension.
- carboxylozatans have an angiotensin II receptor antagonism about 10 to 40 times stronger than rozatans and have a long half-life, which may be useful as a therapeutic agent for hypertension (J Hypertens, 1993 Feb 1 (2): 155-62 and J Chromatogr, 1992 Jan 17 (2): 295-301).
- rozatan is metabolized after absorption and converted to carboxylozatan, and angiotensin II receptor antagonism is increased. The advantage is that such metabolic deviations can be reduced at source.
- the carboxylozatan does not require metabolic processes, so the drug expression may be relatively fast.
- the technical problem to be achieved by the present invention is to provide a carboxylozatan-containing pharmaceutical composition and its preparation method having various advantages.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a solid dispersion in which the carboxylozatan and the water-soluble polymer represented by the following formula (1) are uniformly dispersed (dispersion) contained.
- carboxylojatan has a low elution rate and a low elution rate in a low pH medium, and may cause a decrease in elution rate and elution deviation by agglomeration upon contact with water.
- This drawback of carboxylojatan could be solved by preparing a solid dispersion of carboxylozatan and a water-soluble polymer. That is, the present invention is based on the fact that the dissolution rate at low pH of the carboxylojatan can be improved and the dissolution rate can be improved by preparing the solid dispersion of the carboxylozatan and the water-soluble polymer. By improving the dissolution rate at such low pH, it is thought that the absorption deviation due to pH fluctuations due to food and the like can be reduced, and also the absorption deviation between individuals can be reduced.
- Such water-soluble polymers include polyethylene glycol, polyoxyethylene-polyoxypropylene copolymer, polyvinyl alcohol-polyethylene glycol copolymer, hydroxypropyl cellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, vinylpyrrolidone-vinyl Acetate copolymer, polyvinyl alcohol, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxyethyl methyl cellulose, polyvinylacetate, polyalkene oxide, polyalkenglycol, diethylamino acetate, aminoalkyl methacrylate copolymer, alginic acid Sodium, gelatin and the like can be used alone or in combination.
- the present invention also provides a pharmaceutical composition, characterized in that the water-soluble polymer comprises any one or more selected from the group consisting of polyethylene glycol, polyoxyethylene-polyoxypropylene copolymer and polyvinyl alcohol-polyethylene glycol copolymer to provide.
- the water-soluble polymer comprises any one or more selected from the group consisting of polyethylene glycol, polyoxyethylene-polyoxypropylene copolymer and polyvinyl alcohol-polyethylene glycol copolymer to provide.
- polyethylene glycol also called poly (ethylene glycol) (PEG), poly (ethylene oxide) (PEO) or polyoxyethylene (POE)
- PEG poly (ethylene glycol)
- PEO poly (ethylene oxide)
- POE polyoxyethylene
- polyethylene glycol an average molecular weight of 6000, 4000, 1500, or the like may be used alone or in combination, but is not limited thereto.
- polyethylene glycol 6000 is most preferable in consideration of property stability, ease of manufacture, and the like of the pharmaceutical composition.
- the present invention is a polyethylene glycol polymer and polyethylene, wherein the water-soluble polymer of the solid dispersion is at least one selected from the group consisting of polyethylene glycol, polyoxyethylene-polyoxypropylene copolymer, and polyvinyl alcohol-polyethylene glycol copolymer. It provides a pharmaceutical composition, characterized in that the mixture of a polymer other than the glycol-based polymer.
- a water-soluble polymer that forms a solid dispersion by using a polyethylene glycol-based polymer and another polymer can be used to achieve the optimum dissolution rate and dissolution rate.
- povidone, hydroxypropylmethylcellulose and hydroxypropylcellulose are preferred, and povidone and hydroxypropylmethylcellulose are more preferred.
- the present invention provides a pharmaceutical composition, characterized in that the solid dispersion or pharmaceutical composition comprises silica, crospovidone or a mixture thereof.
- Silica or crospovidone not only serves to improve the dissolution rate and dissolution rate by inhibiting the aggregation of carboxylozatan, but also serves to reduce the dissolution deviation.
- these anti-agglomerates helped the stability of the properties of the pharmaceutical composition containing carboxylozatan.
- Such anti-agglomerating agent may be included in the solid dispersion or mixed after formation of the solid dispersion, but in order to achieve the maximum effect of the anti-agglomerating agent, it is preferably included in the solid dispersion of the carboxylojatan and the water-soluble polymer.
- the solid dispersions and / or pharmaceutical compositions of the present invention may be prepared by conventional excipients, flavoring agents, coloring agents, for the preparation of oral dosage forms (e.g. tablets, granules, capsules, pellets) in addition to the above-mentioned ingredients. It may further include additives such as lubricants, fillers.
- the solid dispersion according to the present invention may be prepared by dissolving constituents such as carboxylozatan and a water-soluble polymer and then drying them, or by melting and cooling the constituents together.
- the solid dispersion of the present invention may be prepared by using such a dissolution process and melting process at once.
- the present invention also includes the steps of preparing a solution in which the (S1) carboxylojatan and the water-soluble polymer are dissolved, and (S2) drying the solution of the step (S1) to prepare a solid dispersion.
- a method for preparing a carboxylozatan-containing pharmaceutical composition having improved dissolution rate and dissolution rate.
- water, ethanol, methanol, isopropyl alcohol, dichloromethane, chloroform, acetone, or the like may be used, but is not limited thereto.
- the drying may be a conventional drying method using hot air, but in order to maintain the mixing uniformity during the drying process, it is preferable that the mixing process is accompanied by a mixing process such as stirring and shaking, and spray drying in terms of mass production.
- a mixing process such as stirring and shaking, and spray drying in terms of mass production.
- the manner is preferred. Fluidized bed granulators, spray dryers, C / F granulators and the like can be used for spray drying.
- the present invention provides a carboxylozatan-containing pharmaceutical composition and a method for preparing the same, wherein the dissolution rate and dissolution rate are improved, and the dissolution deviation according to pH is reduced.
- Carboxylozatan and other additives were simply mixed according to the component and content ratios of Table 1 below, and filled in capsules to prepare Comparative Examples 1 and 1-4.
- Example 1 Example 2
- Example 3 Example 4 Carboxylozatan 10.0 10.0 10.0 10.0 10.0 10.0 Lactose 87.0 77.0 77.0 77.0 77.0
- HPMC means hydroxypropyl methyl cellulose
- HPC means hydroxypropyl cellulose
- Aerosil ® is the trade name of fumed silica
- Kollidon ® CL-SF is the trade name of the fine particle crospovidone to be.
- Comparative Example 1 prepared pH 1.2 buffer (into 2.0 g of sodium chloride, 7.0 ml of hydrochloric acid, purified water 1 liter), pH 4.0 buffer (0.05 mol / L acetate and 0.05 mol / L sodium acetate solution) Mixed (41: 9) to pH 4.0), pH 6.8 buffer (250 ml of 0.2 mol / L potassium dihydrogen phosphate solution 118 ml of 0.2 mol / L sodium hydroxide solution and water to 1 liter) and Elution experiments were performed in purified water.
- the paddle method was used, the amount of the dissolution medium was 900 ml, and the rotation speed of the paddle was 50 rpm. Dissolution rate (%) over time (minutes) is shown in Table 2 below.
- carboxylojatan showed a relatively low dissolution rate and dissolution rate in pH 1.2 buffer. This means that if the pH of the stomach changes due to food intake or the pH of the stomach differs depending on the individual, the absorption of carboxylozatan in the stomach may be different. Therefore, the dissolution rate and dissolution rate of the carboxylozatan in the pH 1.2 buffer It needs to be adjusted. Therefore, in the following dissolution experiments, pH 1.2 buffer was mainly used as the dissolution medium.
- Example 1 Example 2
- Example 3 Example 4 0 0.0 0.0 0.0 0.0 0.0 0.0 5 25.1 24.3 24.8 40.1 10 37.5 39.6 37.8 57.3 15 43.4 45.5 43.7 63.1 30 52.4 55.6 53.4 70.1 45 57.2 61.3 58.4 72.8 60 61.2 65.5 61.9 75.6 90 65.9 69.4 67.0 77.7 120 69.2 72.7 69.6 78.8
- the dissolution rate and the dissolution rate in the pH 1.2 buffer could be improved to some extent, and among the hydrophilic polymers, the dissolution rate and the dissolution rate of the polyethylene glycol were most excellent.
- the water-soluble polymer was dissolved in purified water corresponding to 1 part by weight of the total amount of the water-soluble polymer (polyethylene glycol, povidone, HPMC, and HPC), and then ethanol corresponding to 1 part by weight of the purified water was added. After dissolving the carboxylojatan completely in this solution, lactose; Microcrystalline cellulose; And Aerosil ® or Kollidon ® CL-SF were added and mixed evenly, which was dried at about 40 ° C. After drying, sodium starch glycolate and magnesium stearate were mixed and filled into capsules.
- purified water corresponding to 1 part by weight of the total amount of the water-soluble polymer (polyethylene glycol, povidone, HPMC, and HPC), and then ethanol corresponding to 1 part by weight of the purified water was added. After dissolving the carboxylojatan completely in this solution, lactose; Microcrystalline cellulose; And Aerosil ® or Kollidon ® CL-SF were added and mixed
- Example 5 Example 6
- Example 7 Example 8
- Example 9 Example 10 Rozatan metabolism 10.0 10.0 10.0 10.0 10.0 10.0 10.0 Lactose 77.0 77.0 77.0 72.0 72.0 Microcrystalline cellulose 77.0 77.0 77.0 72.0 72.0 Polyethylene glycol - - - 10.0 10.0 10.0 Povidone 10.0 - - - 10.0 - HPMC - 10.0 - - - 10.0 HPC - - 10.0 - - - Aerosil ® 10.0 - 10.0 10.0 10.0 - KOLLIDON CL-SF ® - 10.0 - - - 10.0 Sodium starch glycolate 14.0 14.0 14.0 14.0 14.0 14.0 Magnesium stearate 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0
- Example 10 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5 36.1 31.0 22.3 44.0 29.4 26.8 10 56.7 43.0 35.3 60.2 53.0 48.4 15 63.7 54.3 44.4 67.3 70.1 62.8 30 74.3 67.9 61.0 77.1 87.7 81.3 45 83.0 74.9 74.7 81.6 93.8 88.1 60 87.7 83.8 78.2 84.7 95.7 91.5 90 90.7 90.5 83.1 88.9 99.0 97.3 120 92.2 91.8 87.5 92.6 101.4 99.8
- Example 9 the dissolution was completed in a short time in all the dissolution medium, it can be seen that the dissolution rate compared to Comparative Example 1. Due to this improvement, the rate of absorption of the carboxylozatan may be increased during the administration of the carboxylozatan, thereby making the delivery of the drug more efficient. In addition, the decrease in dissolution rate and dissolution rate according to pH is expected to significantly reduce the absorption deviation in and between individuals due to the influence of food and the like.
- Example 9 In the same manner as in Example 9, a tablet was prepared to contain 20 mg of carboxylozatan per tablet, and the absorption evaluation experiment was performed using the tablet. The number of subjects was six, and carboxylozatan-containing tablets were administered on an empty stomach with 240 mL of water. Carboxylozatan blood concentration was measured using LC / MS / MS, and the results are shown in FIG.
- the carboxylozatan containing composition according to the present invention showed good absorption.
- Example 9 The average Cmax of the composition was 374.2 ng / ml, the average Tmax was 1.8 hours, and the AUC (last) was about 2209.4.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
(단위: mg) | 비교예 1 | 실시예 1 | 실시예 2 | 실시예 3 | 실시예 4 |
카르복시로자탄 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 |
유당 | 87.0 | 77.0 | 77.0 | 77.0 | 77.0 |
미결정셀룰로오스 | 87.0 | 77.0 | 77.0 | 77.0 | 77.0 |
폴리에틸렌글리콜6000 | - | - | - | - | 10.0 |
포비돈 | - | 10.0 | - | - | - |
HPMC | - | - | 10.0 | - | - |
HPC | - | - | - | 10.0 | - |
Aerosil® | - | 10.0 | - | 10.0 | 10.0 |
KOLLIDON CL-SF® | - | - | 10.0 | - | - |
전분글리콜산나트륨 | 14.0 | 14.0 | 14.0 | 14.0 | 14.0 |
스테아르산마그네슘 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 |
시간(분) | 용출매질에 따른 용출률(%) | |||
pH 1.2 | pH 4.0 | pH 6.8 | 정제수 | |
0 | 0.0 | 0.0 | 0.0 | 0.0 |
5 | 15.5 | 19.1 | 25.3 | 25.1 |
10 | 26.6 | 29.9 | 39.2 | 40.2 |
15 | 31.6 | 34.9 | 47.5 | 48.4 |
30 | 39.5 | 48.7 | 59.7 | 60.3 |
45 | 44.1 | 60.4 | 67.8 | 68.1 |
60 | 46.9 | 69.1 | 71.1 | 72.0 |
90 | 50.6 | 73.5 | 74.9 | 77.3 |
120 | 52.6 | 76.6 | 77.6 | 80.8 |
시간(분) | 용출률(%) | |||
실시예 1 | 실시예 2 | 실시예 3 | 실시예 4 | |
0 | 0.0 | 0.0 | 0.0 | 0.0 |
5 | 25.1 | 24.3 | 24.8 | 40.1 |
10 | 37.5 | 39.6 | 37.8 | 57.3 |
15 | 43.4 | 45.5 | 43.7 | 63.1 |
30 | 52.4 | 55.6 | 53.4 | 70.1 |
45 | 57.2 | 61.3 | 58.4 | 72.8 |
60 | 61.2 | 65.5 | 61.9 | 75.6 |
90 | 65.9 | 69.4 | 67.0 | 77.7 |
120 | 69.2 | 72.7 | 69.6 | 78.8 |
(단위: mg) | 실시예 5 | 실시예 6 | 실시예 7 | 실시예 8 | 실시예 9 | 실시예 10 |
로자탄대사체 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 |
유당 | 77.0 | 77.0 | 77.0 | 77.0 | 72.0 | 72.0 |
미결정셀룰로오스 | 77.0 | 77.0 | 77.0 | 77.0 | 72.0 | 72.0 |
폴리에틸렌글리콜 | - | - | - | 10.0 | 10.0 | 10.0 |
포비돈 | 10.0 | - | - | - | 10.0 | - |
HPMC | - | 10.0 | - | - | - | 10.0 |
HPC | - | - | 10.0 | - | - | - |
Aerosil® | 10.0 | - | 10.0 | 10.0 | 10.0 | - |
KOLLIDON CL-SF® | - | 10.0 | - | - | - | 10.0 |
전분글리콜산나트륨 | 14.0 | 14.0 | 14.0 | 14.0 | 14.0 | 14.0 |
스테아르산마그네슘 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 |
시간(분) | 용출률(%) | |||||
실시예 5 | 실시예 6 | 실시예 7 | 실시예 8 | 실시예 9 | 실시예 10 | |
0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
5 | 36.1 | 31.0 | 22.3 | 44.0 | 29.4 | 26.8 |
10 | 56.7 | 43.0 | 35.3 | 60.2 | 53.0 | 48.4 |
15 | 63.7 | 54.3 | 44.4 | 67.3 | 70.1 | 62.8 |
30 | 74.3 | 67.9 | 61.0 | 77.1 | 87.7 | 81.3 |
45 | 83.0 | 74.9 | 74.7 | 81.6 | 93.8 | 88.1 |
60 | 87.7 | 83.8 | 78.2 | 84.7 | 95.7 | 91.5 |
90 | 90.7 | 90.5 | 83.1 | 88.9 | 99.0 | 97.3 |
120 | 92.2 | 91.8 | 87.5 | 92.6 | 101.4 | 99.8 |
시간(분) | 용출매질에 따른 용출률(%) | |||
pH 1.2 | pH 4.0 | pH 6.8 | 정제수 | |
0 | 0.0 | 0.0 | 0.0 | 0.0 |
5 | 43.3 | 69.8 | 71.8 | 68.2 |
10 | 59.9 | 91.2 | 98.0 | 96.9 |
15 | 75.1 | 97.4 | 100.1 | 98.4 |
30 | 88.7 | 101.0 | 101.3 | 100.1 |
45 | 91.7 | 99.8 | 101.8 | 100.8 |
60 | 94.7 | 100.2 | 102.6 | 100.3 |
90 | 95.9 | 100.6 | 102.7 | 100.6 |
120 | 98.3 | 100.8 | 102.5 | 101.2 |
Claims (6)
- 제 1항에 있어서, 상기 수용성 고분자는 폴리에틸렌글리콜, 폴리옥시에틸렌-폴리옥시프로필렌 공중합체, 폴리비닐알코올-폴리에틸렌글리콜 공중합체, 히드록시프로필셀룰로스, 히드록시프로필메틸셀룰로스, 폴리비닐피롤리돈, 비닐피롤리돈-비닐아세테이트 공중합체, 폴리비닐알코올, 히드록시메틸셀룰로오스, 히드록시에틸셀룰로오스, 히드록시에틸메틸셀룰로오스, 폴리비닐아세테이트, 폴리알켄옥사이드, 폴리알켄글리콜, 디에틸아미노아세테이트, 아미노알킬메타크릴레이트 공중합체, 알긴산나트륨 및 젤라틴으로 이루어진 군으로부터 선택된 어느 하나 이상인 것을 특징으로 하는 약학 조성물.
- 제 2항에 있어서, 상기 수용성 고분자는 폴리에틸렌글리콜, 폴리옥시에틸렌-폴리옥시프로필렌 공중합체 및 폴리비닐알코올-폴리에틸렌글리콜 공중합체로 이루어진 군으로부터 선택된 어느 하나 이상을 포함하는 것을 특징으로 하는 약학 조성물.
- 제 3항에 있어서, 상기 수용성 고분자는 폴리에틸렌글리콜, 폴리옥시에틸렌-폴리옥시프로필렌 공중합체 및 폴리비닐알코올-폴리에틸렌글리콜 공중합체로 이루어진 군으로부터 선택된 어느 하나 이상의 폴리에틸렌글리콜계 수용성 고분자와 폴리에틸렌글리콜계 수용성 고분자 이외의 다른 수용성 고분자의 혼합물인 것을 특징으로 하는 약학 조성물.
- 제 1항 내지 제 4항 중 어느 한 항에 있어서, 상기 고체분산체는 실리카, 크로스포비돈 또는 이들의 혼합물을 포함하는 것을 특징으로 하는 약학 조성물.
- 제 1항 내지 제 4항 중 어느 한 항에 있어서, 상기 약학 조성물은 실리카, 크로스포비돈 또는 이들의 혼합물을 포함하는 것을 특징으로 하는 약학 조성물.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201080028788.7A CN102802611B (zh) | 2009-06-25 | 2010-06-25 | 含氯沙坦羧酸的药物组合物及其生产方法 |
EP10792362.5A EP2446879B1 (en) | 2009-06-25 | 2010-06-25 | Pharmaceutical composition containing carboxylosartan and a production method therefor |
KR1020117030206A KR101817986B1 (ko) | 2009-06-25 | 2010-06-25 | 카르복시로자탄을 함유하는 약학 조성물 및 이의 제조방법 |
US13/380,266 US20120095067A1 (en) | 2009-06-25 | 2010-06-25 | Pharmaceutical composition containing carboxylosartan and a production method therefor |
JP2012517397A JP5442116B2 (ja) | 2009-06-25 | 2010-06-25 | ロサルタンカルボン酸を含有する薬学組成物及びその製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2009-0057054 | 2009-06-25 | ||
KR20090057054 | 2009-06-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010151080A2 true WO2010151080A2 (ko) | 2010-12-29 |
WO2010151080A3 WO2010151080A3 (ko) | 2011-05-19 |
Family
ID=43387070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/004152 WO2010151080A2 (ko) | 2009-06-25 | 2010-06-25 | 카르복시로자탄을 함유하는 약학 조성물 및 이의 제조방법 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20120095067A1 (ko) |
EP (1) | EP2446879B1 (ko) |
JP (1) | JP5442116B2 (ko) |
KR (1) | KR101817986B1 (ko) |
CN (1) | CN102802611B (ko) |
WO (1) | WO2010151080A2 (ko) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2238975A1 (en) * | 1995-12-12 | 1997-06-19 | Merck & Co., Inc. | New use for losartan |
WO1999043210A1 (en) * | 1998-02-25 | 1999-09-02 | Merck & Co., Inc. | Method for decreasing qt dispersion or inhibiting the progression of qt dispersion with an angiotensin ii receptor antagonist |
US6723340B2 (en) * | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
KR100582347B1 (ko) * | 2004-12-30 | 2006-05-22 | 한미약품 주식회사 | 3-하이드록시-3-메틸글루타릴 조효소 a 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법 |
ITMI20050551A1 (it) * | 2005-04-01 | 2006-10-02 | Dipharma Spa | Forma cristallina alfa di losartan potassio |
MX2007012947A (es) * | 2005-04-18 | 2008-04-09 | Rubicon Res Pvt Ltd | Composiciones biomejoradas. |
CA2604190A1 (en) * | 2005-04-20 | 2006-11-02 | Merck & Co., Inc. | Angiotensin ii receptor antagonists |
JP4965096B2 (ja) * | 2005-08-19 | 2012-07-04 | テバ製薬株式会社 | 圧縮成型製剤 |
TW200734304A (en) * | 2005-11-08 | 2007-09-16 | Astellas Pharma Inc | Benzene derivative or salt thereof |
GB0613925D0 (en) * | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
US20100008956A1 (en) * | 2008-07-08 | 2010-01-14 | Jie Du | Composition and combinations of carboxylic acid losartan in dosage forms |
-
2010
- 2010-06-25 CN CN201080028788.7A patent/CN102802611B/zh not_active Expired - Fee Related
- 2010-06-25 JP JP2012517397A patent/JP5442116B2/ja not_active Expired - Fee Related
- 2010-06-25 US US13/380,266 patent/US20120095067A1/en not_active Abandoned
- 2010-06-25 WO PCT/KR2010/004152 patent/WO2010151080A2/ko active Application Filing
- 2010-06-25 EP EP10792362.5A patent/EP2446879B1/en not_active Not-in-force
- 2010-06-25 KR KR1020117030206A patent/KR101817986B1/ko active IP Right Grant
Non-Patent Citations (2)
Title |
---|
J CHROMATOGR, vol. 2, 17 January 1992 (1992-01-17), pages 295 - 301 |
J HYPERTENS, vol. 2, 1 February 1993 (1993-02-01), pages 155 - 62 |
Also Published As
Publication number | Publication date |
---|---|
CN102802611A (zh) | 2012-11-28 |
US20120095067A1 (en) | 2012-04-19 |
WO2010151080A3 (ko) | 2011-05-19 |
JP5442116B2 (ja) | 2014-03-12 |
EP2446879A2 (en) | 2012-05-02 |
EP2446879B1 (en) | 2014-02-12 |
KR101817986B1 (ko) | 2018-01-16 |
CN102802611B (zh) | 2014-11-12 |
KR20120111935A (ko) | 2012-10-11 |
JP2012530778A (ja) | 2012-12-06 |
EP2446879A4 (en) | 2012-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005105036A1 (en) | Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation | |
JP2005508331A (ja) | 糖尿病の処置のための投与製剤 | |
WO2013087546A1 (en) | Pharmaceutical composition with improved bioavailability for high melting hydrophobic compound | |
WO2022012172A1 (zh) | 一种难溶性药物口服缓释组合物及其制备方法 | |
AU2002350082B9 (en) | Process for preparing quick dissolving, high loading ribavirin compositions | |
WO2020138791A2 (ko) | 토파시티닙 또는 그의 약제학적으로 허용되는 염을 함유한 서방성 제제 및 그의 제조방법 | |
US5213806A (en) | Pharmaceutical composition comprising calcium polycarbophil | |
JP7132947B2 (ja) | 改善された持続放出性高充填薬物組成物 | |
WO2010090371A1 (en) | Aceclofenac-containing controlled-release oral drug preparations and their manufacturing process | |
WO2013169925A1 (en) | Novel formulations of nitrofurans including nifurtimox with enhanced activity with lower toxicity | |
WO2011037281A1 (ko) | 용출률 향상과 부작용 발현이 최소화된 실로스타졸 서방정 | |
EP1146864B1 (en) | Ph independent extended release pharmaceutical formulation | |
CA2517120C (en) | Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof | |
WO2019245309A1 (en) | A sustained release pharmaceutical preparation comprising tacrolimus | |
CN101084904B (zh) | 头孢克肟缓释双层片 | |
CN1832736A (zh) | 加巴喷丁的稳定缓释口服剂型 | |
WO2010151080A2 (ko) | 카르복시로자탄을 함유하는 약학 조성물 및 이의 제조방법 | |
CN114246836B (zh) | 一种普瑞巴林缓释片及其制备方法 | |
WO2017116031A1 (ko) | 유당불내성 환자에게 투여가 가능하며, 복용편의성이 향상된 게피티니브를 함유하는 약제학적 조성물 | |
WO2016133333A2 (en) | An oral pharmaceutical formulation comprising sustained-release granules containing tamsulosin hydrochloride | |
WO2013095042A2 (ko) | 이매티닙메실산염 함유 과립, 이를 포함하는 경구용 속방성 정제 조성물 및 그것의 제조방법 | |
TWI823471B (zh) | 沙庫巴曲纈沙坦鈉緩釋組合物、其製備方法及應用 | |
AU2004226898B2 (en) | Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof | |
WO2012111965A2 (ko) | 경구투여용 탐술로신 또는 이의 약제학적으로 허용되는 염을 포함하는 서방성 삼중정제 | |
EP2389174A2 (en) | Chronotherapeutic pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080028788.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10792362 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 20117030206 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012517397 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13380266 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010792362 Country of ref document: EP |